Executive Summary
Prior literature documents cases of airborne infectious disease transmission at distances ranging from ≥ 2 m to inter-continental in scale. Physics- and biology- based models describe the key aspects of these airborne disease transmission events, but important gaps remain. This report extends current approaches by developing a new, single-particle based theory that (a) assesses the likelihood of rare airborne infections (where individuals inhale either one or no infectious particles) and (b) explicitly accounts for the variability in airborne exposures and population susceptibilities within a geographic region of interest. For these hazards, airborne particle fate and transport is independent of particulate concentration, and so results for complex releases can be determined from the results of many single-particle releases.
This work is intended to provide context for both (a) the initial stages of a disease outbreak and (b) larger scale (≥ 2 m) disease spread, including distant disease “sparks” (low probability, unexpected disease transmission events that infect remote, susceptible populations). The physics of airborne particulate dispersion inherently constrains airborne disease transmission. As such, this work suggests results that, a priori, may be applicable to many airborne diseases.
Model Predictions
Modeling predictions of the single-particle transmission kernel suggest that outdoor airborne disease transmission events may occur episodically as the infection probabilities can vary over many orders of magnitude depending on the distance downwind; specific virus, prion, or microorganism; and meteorological conditions.
Model results suggest that, under the right conditions, an indoor infected person could spread disease to a similar, or greater, number of people downwind than in the building they occupy. However, the downwind, per-person infection probability is predicted to be lower than the within-building, per-person infection probability. This finding is limited to airborne transmission considerations.
This work suggests a new relative disease probability metric for airborne transmitted diseases. This metric, which is distinct from the traditional relative risk metric, is applicable when the rate at which the infectious agent losses infectivity in the atmosphere is ≲ 1 h-1.
Competing Interest Statement
MBD was supported, in part, by the US Department of Homeland Security. Outside the scope of this work, MBD collaborates with the University of Texas Medical Branch.
Funding Statement
This work was supported, in part, by the US Department of Homeland Security.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Auspices and Disclaimer
This work was performed under the auspices of the U.S. Department of Energy by Lawrence Livermore National Laboratory under Contract DE-AC52-07NA27344.
This document was prepared as an account of work sponsored by an agency of the United States government. Neither the United States government nor Lawrence Livermore National Security, LLC, nor any of their employees makes any warranty, expressed or implied, or assumes any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed, or represents that its use would not infringe privately owned rights. Reference herein to any specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise does not necessarily constitute or imply its endorsement, recommendation, or favoring by the United States government or Lawrence Livermore National Security, LLC. The views and opinions of authors expressed herein do not necessarily state or reflect those of the United States government or Lawrence Livermore National Security, LLC, and shall not be used for advertising or product endorsement purposes.
↵30 airborne microbial threats to animal livestock or resulting from agricultural activities
↵31 The airborne disease transmission pathway can contribute to overall disease transmission, even when other – droplet (> 5 μm AD particles) and contact – pathways are important, e.g., [6], [7].
↵32 The physics of outdoor-origin particles penetrating buildings and exposing indoor individuals has been studied, e.g., [30] and is demonstrated by (a) indoor measurements of outdoor-origin PM2.5 particles [34], [119] and (b) airborne Bacillus thuringiensis bacteria infiltration into buildings [23].
↵33 The number of particles required to change the behavior of the atmospheric depends on the (a) atmospheric volume of interest, (b) particle size and density, (c) release duration, and (d) ambient wind speed [9]. For context, assuming a light wind (1 m s-1) and monodisperse particles as dense as water (1000 kg m-3); a 1 m3 release volume can contain at least 1016 0.1 µm diameter particles, 1013 1 µm diameter particles, or 1010 10 µm diameter particles without violating this assumption.
↵34 These computational marker particles are a large sample from the possible particles emitted and are used in estimating downwind concentrations along the prescribed contaminant emission amount. These particles do NOT directly represent individual physical aerosols.
↵35 Respiratory minute volume is a traditional unit in pulmonary medicine – this study uses respiratory second volume.
↵36 For context, an airborne exposure of 104 particles s m-3 would result in a typical individual inhaling a single particle (assuming a breathing rate of 10−4 m3 s-1 [235]).
↵37 One example is a group of people in a room where the air is well mixed.
↵38 One example is a neighborhood where people are in different buildings that provide varying degrees of protection from an outdoor plume of airborne, infectious particles.
↵39 We note that the contaminants of concern here are from the outdoors which, due to the air change mechanisms, can result in a relatively uniform indoor spatial contaminant distribution. For example in modeling indoor concentrations of outdoor ozone, Hayes [241] demonstrated that the indoor/outdoor ozone concentration ratio was insensitive to the degree of indoor mixing in both single- and multicompartment models for residences and office buildings. For context, the mixing time constants for both buoyant and mechanical flow conditions in laboratory studies of room mixing are short, 10 min to < 1 h, compared to the exposure times of interest [35], [36].
↵40 These equations assume that (a) initial (t = 0) indoor air concentrations are zero and (b) material removed from the indoor air is not reintroduced at a later time (e.g., resuspension of deposited particles).
↵41 These computational marker particles are a large sample from the possible particles emitted and are used in estimating downwind concentrations along the prescribed contaminant emission amount. These particles do NOT directly represent individual physical aerosols.
↵42 The dose required to infect 50% of the human subjects is 1.18 bacteria (95% CI: 0.76 to 40.2) [15], [83].
↵43 Coxiella antibody “Phases” are a laboratory methods notation where Phase 1 antibodies occur first in embryonated egg cultures and Phase II antibodies later. In human Acute Q Fever, Phase II antibodies peak first at high levels (≥ 1:128) 1 to 2 weeks after the start of symptoms when Phase I antibody levels are low. Phase I antibodies peak some weeks after. Our selective acute infection criteria was chosen to reflect these dynamics and relevant human levels [61], [249].
↵44 In the US there is mandatory reporting of Q Fever to the US Centers for Disease Control and Prevention national disease reporting system, see https://www.cdc.gov/qfever/info/index.html.
↵45 The NHANES survey provides nationally representative estimates using a demographically-based complex, multistage survey design to minimize bias [62], [257].
46 Antibody prevalence in men and woman was 3.8% and 2.5%, respectively.
47 NHANES 2003 to 2004 demographics and Coxiella serology data were downloaded from the NHANES website. Data assembly and analysis used SAS™ (Release 9.4, SAS Institute, Inc., Cary, NC). Survey design variables (strata and primary sampling units) and survey sample weights were used to account for differential probabilities of participant selection in the complex multistage survey design. Sample weights provide nationally representative estimates and adjust estimates for nonresponse and noncoverage. Statistical estimates are age-adjusted to the US population. Results with relative standard errors >30%, with <12 degrees of freedom, or low sample sizes are not presented.
Data Availability
Data provided in supplemental materials.
